NCT01664533View on ClinicalTrials.gov

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

Erlotinib

Erlotinib was supplied as tablets in the retail product Tarceva.

Trial Locations (21)

1200

Brussels

1340

Ottignies

2020

Antwerp

2300

Turnhout

2570

Duffel

2650

Edegem

3600

Genk

4000

Liège

4420

Montegnée

5000

Namur

6000

Charleroi

6041

Gosselies

6060

Gilly

7000

Mons

7080

Frameries

7360

Boussu

7500

Tournai

8800

Roeselare

9100

Sint-Niklaas

9200

Dendermonde

9300

Aalst

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01664533 - An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy | Biotech Hunter | Biotech Hunter